Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
11.28-0.47 (-4.00%)
At close: 04:00PM EDT
11.38 +0.10 (+0.89%)
After hours: 06:03PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close11.75
Open11.61
Bid11.08 x 1300
Ask11.95 x 800
Day's Range11.10 - 11.63
52 Week Range7.40 - 18.93
Volume349,762
Avg. Volume499,798
Market Cap606.028M
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CARA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cara Therapeutics, Inc.
    CARA: What does Argus have to say about CARA?CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Cara Therapeutics Reports Second Quarter 2022 Financial Results

    – Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI

  • GlobeNewswire

    Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

    STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET. A webcast of the presentation can be accessed under "Events & Presentations"

  • GlobeNewswire

    Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

    STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to report second quarter 2022 financial results and provide a corporate update. To participate in the conference call, please register here. Registrant

Advertisement
Advertisement